Recently, the sub journal Nature Cancer published an article reviewing the approval status of new cancer drugs in 2024, as well as the research and development progress of other anti-cancer therapies. In today's article, the WuXi AppTec content team will review the progress and innovations in the field of cancer treatment over the past year with readers, combining publicly available information with this viewpoint article. These advances not only have profound impacts on patients and healthcare workers, but also foreshadow the future direction of cancer treatment.
Cell therapy has made significant achievements in the field of hematological oncology. However, solid tumors pose significant challenges for the application of cell therapy due to their immunosuppressive tumor microenvironment and heterogeneity in antigen expression. In 2024, the first T-cell therapy for solid tumors was successfully approved, marking a new era for cell therapy and opening up broader prospects for the treatment of various types of tumors.
In May 2024, the FDA approved the marketing of the bispecific T cell conjugator (BiTE) Imdelltra (tarlatamab) targeting CD3 and DLL3 for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC). This approval marks Imdelltra as the first BiTE therapy for treating solid tumors. With the approval of Imdelltra, targeted research on DLL3 has gained new momentum, and several bispecific, trispecific antibodies and antibody conjugated drugs (ADCs) targeting DLL3 are currently in the clinical development stage.
Significant progress has been made in other innovative immunotherapy drugs in 2024. In the same year, innovative therapies such as the bispecific antibody Ziihera (zanidatmab), IL-15 receptor super agonist Anktiva, and the antibody Vyloy (zolbetuximab) targeting Claudin18.2 (CLDN18.2) were successively launched, which were respectively used to treat biliary tract cancer, non muscle invasive bladder cancer cancer, gastric cancer, or adenocarcinoma of the gastroesophageal junction (GEJ). These therapies are all "first in class" therapies in their respective fields of treatment. Specifically, Jazz Pharmaceuticals announced in its press release that Ziihera is the first HER2 targeted bispecific antibody approved by the FDA for the treatment of HER2 positive cholangiocarcinoma. Anktiva is the first IL-15 receptor super agonist used to treat non muscle invasive bladder cancer without response to BCG and accompanied by carcinoma in situ; Vyloy is the first CLDN18.2 targeted therapy approved by the US FDA. The launch of these breakthrough therapies provides patients with new treatment options and may change the future landscape of cancer treatment.
In 2024, people have high hopes for drug development targeting KRAS protein, especially in seeking breakthroughs in mutations beyond KRAS G12C. Revolution Medicines has developed a selective drug RMC-9805 targeting KRAS G12D. According to phase 1 clinical trial data, the disease control rate of pancreatic ductal adenocarcinoma (PDAC) patients treated with RMC-9805 is as high as 80%, demonstrating the potential for treating PDAC.
2024 is a year full of breakthroughs in the field of cancer treatment, among which the progress of T cell therapy for solid tumors is particularly remarkable. Meanwhile, new small molecule drugs provide new targeted treatment options for difficult to treat cancers. Looking ahead to 2025, we look forward to seeing the emergence of more innovative therapies and witnessing them reshape the landscape of cancer treatment, bringing good news to patients.
<Reprinted from WuXi AppTec>




![1454849-17-2 2-[(1R)-1-[(2-AMINO-5-BROMOPYRIDIN-3-YL)OXY]ETHYL]-4-FLUOROBENZOIC ACID](/uploads/41320/page/small/1454849-17-2-2-1r-1-2-amino-5-bromopyridin-36a494.jpg?size=331x0)


